- Home
- NBTB vs BLTE Comparison
NBTB vs BLTE Comparison
Compare NBTB & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTB
- BLTE
- Stock Information
- Founded
- NBTB 1856
- BLTE 2018
- Country
- NBTB United States
- BLTE United States
- Employees
- NBTB N/A
- BLTE N/A
- Industry
- NBTB Major Banks
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- NBTB Finance
- BLTE Health Care
- Exchange
- NBTB Nasdaq
- BLTE Nasdaq
- Market Cap
- NBTB 2.2B
- BLTE 2.1B
- IPO Year
- NBTB N/A
- BLTE 2022
- Fundamental
- Price
- NBTB $43.76
- BLTE $64.50
- Analyst Decision
- NBTB Buy
- BLTE Strong Buy
- Analyst Count
- NBTB 4
- BLTE 4
- Target Price
- NBTB $51.00
- BLTE $96.67
- AVG Volume (30 Days)
- NBTB 181.5K
- BLTE 69.4K
- Earning Date
- NBTB 07-28-2025
- BLTE 08-08-2025
- Dividend Yield
- NBTB 3.16%
- BLTE N/A
- EPS Growth
- NBTB 7.39
- BLTE N/A
- EPS
- NBTB 2.77
- BLTE N/A
- Revenue
- NBTB $591,283,000.00
- BLTE N/A
- Revenue This Year
- NBTB $26.43
- BLTE N/A
- Revenue Next Year
- NBTB $12.13
- BLTE N/A
- P/E Ratio
- NBTB $15.51
- BLTE N/A
- Revenue Growth
- NBTB 14.42
- BLTE N/A
- 52 Week Low
- NBTB $37.31
- BLTE $43.70
- 52 Week High
- NBTB $52.44
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- NBTB 53.72
- BLTE 58.14
- Support Level
- NBTB $41.07
- BLTE $59.12
- Resistance Level
- NBTB $44.22
- BLTE $62.64
- Average True Range (ATR)
- NBTB 1.33
- BLTE 1.78
- MACD
- NBTB -0.17
- BLTE 0.27
- Stochastic Oscillator
- NBTB 56.16
- BLTE 78.64
About NBTB NBT Bancorp Inc.
NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. Its business, predominantly conducted through NBT Bank, consists of providing commercial banking, retail banking, and wealth management services to customers in its market area, which includes upstate New York, northeastern Pennsylvania, southern New Hampshire, western Massachusetts, Vermont, southern Maine, and central and northwestern Connecticut. The company's reportable segments are Banking and Retirement Plan Administration. A majority of its revenue is generated from the Banking segment.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.